<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00048724</url>
  </required_header>
  <id_info>
    <org_study_id>P02569</org_study_id>
    <nct_id>NCT00048724</nct_id>
  </id_info>
  <brief_title>Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)</brief_title>
  <official_title>PEG-Intron as Maintenance Therapy vs. an Untreated Control Group in Adult Subjects With Compensated Cirrhosis (METAVIR F4), Secondary to Chronic Hepatitis C, Who Have Failed to Respond to Therapy With Any Alpha Interferon Plus Ribavirin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety and efficacy of PEG-Intron vs. no
      treatment for the prevention of disease progression in adult subjects with compensated
      cirrhosis secondary to chronic hepatitis C, who failed to respond to therapy with an a
      interferon plus ribavirin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Observation of the First Clinical Event Experienced by a Subject</measure>
    <time_frame>Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event</time_frame>
    <description>Clinical events are liver decompensation [variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites], hepatic carcinoma, death, and/or liver transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Observation of the Disease Progression Experienced by a Subject</measure>
    <time_frame>Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event</time_frame>
    <description>Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">631</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>PegIntron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PegIntron (peginterferon alfa-2b) 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Untreated Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peginterferon alfa-2b (SCH 54031)</intervention_name>
    <description>0.5 µg/kg subcutaneously once weekly for 60 months</description>
    <arm_group_label>PegIntron</arm_group_label>
    <other_name>PegIntron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at entry 18-65 years;

          -  Non-responders to previous treatment (minimum of 3 months) with an alpha interferon
             plus ribavirin;

          -  Liver biopsy demonstrating cirrhosis

        Exclusion Criteria:

          -  Any other cause for liver disease other than chronic hepatitis C;

          -  History or presence of complications of cirrhosis;

          -  Alcohol or illicit drug abuse or treatment with methadone within the past 2 years;

          -  Diseases or conditions that could interfere with participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Puerto Rico</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2002</study_first_submitted>
  <study_first_submitted_qc>November 7, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2002</study_first_posted>
  <results_first_submitted>April 23, 2009</results_first_submitted>
  <results_first_submitted_qc>April 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 11, 2009</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C; Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Analysis population is modified intent to treat (MITT), comprising 626 randomized subjects from sites compliant with GCP (Good Clinical Practice). Two sites were closed due to GCP noncompliance, and the 5 subjects from these sites were excluded from analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PegIntron</title>
          <description>PegIntron 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up</description>
        </group>
        <group group_id="P2">
          <title>Untreated Control</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="311"/>
                <participants group_id="P2" count="315"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="195"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="118"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol-defined Clinical Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance With Protocol</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did Not Meet Protocol Eligibility</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PegIntron</title>
          <description>PegIntron 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up</description>
        </group>
        <group group_id="B2">
          <title>Untreated Control</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="311"/>
            <count group_id="B2" value="315"/>
            <count group_id="B3" value="626"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="100"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="215"/>
                    <measurement group_id="B3" value="421"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Observation of the First Clinical Event Experienced by a Subject</title>
        <description>Clinical events are liver decompensation [variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites], hepatic carcinoma, death, and/or liver transplantation</description>
        <time_frame>Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event</time_frame>
        <population>Analysis population is modified intent to treat (MITT), comprising all randomized subjects from sites compliant with GCP (Good Clinical Practice). Two sites were closed due to GCP noncompliance, and the 5 subjects from these sites were excluded from efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PegIntron</title>
            <description>PegIntron 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Observation of the First Clinical Event Experienced by a Subject</title>
          <description>Clinical events are liver decompensation [variceal bleeding, development of Child-Pugh Class C, hepatic encephalopathy ≥Grade 2, ascites], hepatic carcinoma, death, and/or liver transplantation</description>
          <population>Analysis population is modified intent to treat (MITT), comprising all randomized subjects from sites compliant with GCP (Good Clinical Practice). Two sites were closed due to GCP noncompliance, and the 5 subjects from these sites were excluded from efficacy analyses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;6 to 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;12 to 18 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;18 to 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;24 to 30 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;30 to 36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;36 to 42 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;42 to 48 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;48 to 54 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;54 to 60 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Over Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary scientific hypothesis is that, 0.5 ug/kg subcutaneous once weekly PegIntron as maintenance therapy is efficacious, when compared to no treatment, in the prevention of clinical events in adult subjects with compensated cirrhosis (Metavir F4), secondary to Chronic Hepatitis C, who have failed to respond to therapy with any α interferon plus ribavirin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1439</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Age (&lt;= 50 years, &gt;50 years) and participation in a prior study (yes, no) were stratification factors.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.452</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.880</ci_lower_limit>
            <ci_upper_limit>2.396</ci_upper_limit>
            <estimate_desc>Hazard ratio represents results of untreated control relative to treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observation of the Disease Progression Experienced by a Subject</title>
        <description>Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.</description>
        <time_frame>Up to 60 months of treatment or observation, or when 98 subjects experience at least one clinical event</time_frame>
        <population>Analysis population is modified intent to treat (MITT), comprising all randomized subjects from sites compliant with GCP (Good Clinical Practice). Two sites were closed due to GCP noncompliance, and the 5 subjects from these sites were excluded from efficacy analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PegIntron</title>
            <description>PegIntron 0.5 µg/kg subcutaneously once weekly as maintenance therapy for 60 months with a 4-week post-treatment follow-up</description>
          </group>
          <group group_id="O2">
            <title>Untreated Control</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Observation of the Disease Progression Experienced by a Subject</title>
          <description>Disease progression was observation of any clinical event defined for the primary outcome, plus any of development of Child-Pugh Class B, emergence of varices, or enlargement of pre-existing varices requiring additional therapy.</description>
          <population>Analysis population is modified intent to treat (MITT), comprising all randomized subjects from sites compliant with GCP (Good Clinical Practice). Two sites were closed due to GCP noncompliance, and the 5 subjects from these sites were excluded from efficacy analyses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="315"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;6 to 12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;12 to 18 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;18 to 24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;24 to 30 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;30 to 36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;36 to 42 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;42 to 48 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;48 to 54 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;54 to 60 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Over Study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The secondary hypothesis is that 0.5 ug/kg subcutaneous once weekly PegIntron as maintenance therapy is efficacious, when compared to no treatment, in the prevention of disease progression in adult subjects with compensated cirrhosis (Metavir F4), secondary to Chronic Hepatitis C, who have failed to respond to therapy with any α interferon plus ribavirin.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0070</p_value>
            <method>Cox Proportional Hazards Model</method>
            <method_desc>Age (&lt;= 50 years, &gt;50 years) and participation in a prior study (yes, no) were stratification factors.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.564</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.130</ci_lower_limit>
            <ci_upper_limit>2.166</ci_upper_limit>
            <estimate_desc>Hazard ratio represents results of untreated control relative to treatment.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>PegIntron</title>
        </group>
        <group group_id="E2">
          <title>Untreated Control</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>AUTOIMMUNE THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>HEARING IMPAIRED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>TINNITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT NUCLEAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DIABETIC RETINOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RETINAL DETACHMENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GASTRIC VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GASTRITIS EROSIVE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HERNIAL EVENTRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ILEITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MALLORY-WEISS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MELAENA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL VARICES HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RECTAL FISSURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="8" subjects_affected="4" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILIARY COLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CHRONIC HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEPATIC MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LIVER DISORDER</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PORTAL HYPERTENSIVE GASTROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL WALL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BRONCHIECTASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FEBRILE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HAEMOPHILUS SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISCITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MENINGITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PILONIDAL CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PSOAS ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SUBCUTANEOUS ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>TOOTH INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CERVICAL VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DISLOCATION OF VERTEBRA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FOOT FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LUMBAR VERTEBRAL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MENISCUS LESION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NECK INJURY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL FISTULA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE FEVER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SKULL FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>THERMAL BURN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>WOUND SECRETION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>WRIST FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALPHA 1 FOETOPROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>TRANSPLANT EVALUATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DIABETES WITH HYPEROSMOLARITY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>EXTRASKELETAL OSSIFICATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FOOT DEFORMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LUMBAR SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OSTEONECROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BREAST CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BREAST CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEPATIC NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="311"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MALIGNANT PALATE NEOPLASM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MULTIPLE MYELOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL CANCER STAGE UNSPECIFIED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RECTAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SALIVARY GLAND ADENOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CARPAL TUNNEL SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CEREBRAL CYST</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEPATIC ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HYPERTONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INTRACRANIAL ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MENINGORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL ABUSE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BRADYPHRENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BREAST CALCIFICATIONS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CYSTOCELE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MENORRHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OVARIAN CYST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>UTERINE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>UTERINE PROLAPSE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INTERSTITIAL LUNG DISEASE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MIDDLE LOBE SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>POST PROCEDURAL DRAINAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ILIAC ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>LYMPHOEDEMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PELVIC VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VARICOSE VEIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VASCULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="311"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="290" subjects_at_risk="311"/>
                <counts group_id="E2" subjects_affected="260" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="31" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="119" subjects_affected="43" subjects_at_risk="311"/>
                <counts group_id="E2" events="26" subjects_affected="18" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SPLENOMEGALY</sub_title>
                <counts group_id="E1" events="69" subjects_affected="60" subjects_at_risk="311"/>
                <counts group_id="E2" events="61" subjects_affected="54" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="122" subjects_affected="52" subjects_at_risk="311"/>
                <counts group_id="E2" events="41" subjects_affected="20" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="40" subjects_affected="33" subjects_at_risk="311"/>
                <counts group_id="E2" events="27" subjects_affected="21" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="66" subjects_affected="45" subjects_at_risk="311"/>
                <counts group_id="E2" events="67" subjects_affected="46" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="57" subjects_affected="37" subjects_at_risk="311"/>
                <counts group_id="E2" events="30" subjects_affected="25" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" events="29" subjects_affected="21" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" events="42" subjects_affected="40" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="62" subjects_affected="49" subjects_at_risk="311"/>
                <counts group_id="E2" events="58" subjects_affected="39" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VARICES OESOPHAGEAL</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="311"/>
                <counts group_id="E2" events="56" subjects_affected="52" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="311"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="70" subjects_affected="45" subjects_at_risk="311"/>
                <counts group_id="E2" events="48" subjects_affected="37" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="37" subjects_affected="26" subjects_at_risk="311"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="152" subjects_affected="103" subjects_at_risk="311"/>
                <counts group_id="E2" events="92" subjects_affected="78" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="61" subjects_affected="46" subjects_at_risk="311"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INJECTION SITE ERYTHEMA</sub_title>
                <counts group_id="E1" events="37" subjects_affected="36" subjects_at_risk="311"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="48" subjects_affected="41" subjects_at_risk="311"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MALAISE</sub_title>
                <counts group_id="E1" events="41" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="311"/>
                <counts group_id="E2" events="39" subjects_affected="29" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="163" subjects_affected="57" subjects_at_risk="311"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATOMEGALY</sub_title>
                <counts group_id="E1" events="61" subjects_affected="45" subjects_at_risk="311"/>
                <counts group_id="E2" events="62" subjects_affected="51" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" events="38" subjects_affected="23" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="311"/>
                <counts group_id="E2" events="37" subjects_affected="28" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="27" subjects_affected="20" subjects_at_risk="311"/>
                <counts group_id="E2" events="36" subjects_affected="25" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="23" subjects_affected="17" subjects_at_risk="311"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="20" subjects_affected="9" subjects_at_risk="311"/>
                <counts group_id="E2" events="22" subjects_affected="16" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" events="32" subjects_affected="25" subjects_at_risk="311"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="27" subjects_affected="21" subjects_at_risk="311"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="120" subjects_affected="68" subjects_at_risk="311"/>
                <counts group_id="E2" events="90" subjects_affected="63" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="47" subjects_affected="44" subjects_at_risk="311"/>
                <counts group_id="E2" events="51" subjects_affected="39" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="311"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="242" subjects_affected="76" subjects_at_risk="311"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="36" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="32" subjects_affected="22" subjects_at_risk="311"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="249" subjects_affected="103" subjects_at_risk="311"/>
                <counts group_id="E2" events="62" subjects_affected="47" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="46" subjects_affected="24" subjects_at_risk="311"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="41" subjects_affected="35" subjects_at_risk="311"/>
                <counts group_id="E2" events="35" subjects_affected="26" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="77" subjects_affected="50" subjects_at_risk="311"/>
                <counts group_id="E2" events="55" subjects_affected="45" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL CYST</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="311"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="46" subjects_affected="33" subjects_at_risk="311"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="311"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="311"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="41" subjects_affected="36" subjects_at_risk="311"/>
                <counts group_id="E2" events="30" subjects_affected="27" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="64" subjects_affected="42" subjects_at_risk="311"/>
                <counts group_id="E2" events="38" subjects_affected="27" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="41" subjects_affected="31" subjects_at_risk="311"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="315"/>
              </event>
              <event>
                <sub_title>SPIDER NAEVUS</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="311"/>
                <counts group_id="E2" events="19" subjects_affected="17" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="47" subjects_affected="41" subjects_at_risk="311"/>
                <counts group_id="E2" events="40" subjects_affected="38" subjects_at_risk="315"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide review copies to the sponsor 30 days prior to submission for publication or presentation. The sponsor shall have editorial rights and the right to review and comment on the data analysis and presentation. If the parties disagree, investigator agrees to meet with the sponsor's representatives for the purpose of making good faith efforts to discuss and resolve any such issues.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

